Oncopeptides AB (STO:ONCO) on Friday announced the presentation of new data at the 24th Congress of the European Haematology Association (EHA) in Amsterdam, including updated interim data from the ongoing phase 1/2 ANCHOR study and data from its phase 1/2 O-12-M1 study.

The company said that interim data from its ongoing, pivotal phase 2 HORIZON trial will also be presented on 16 June 2019 as an oral presentation by Professor Paul G. Richardson, Professor of Medicine at Harvard Medical School and clinical programme leader, director of Clinical Research at the Jerome Lipper Multiple Myeloma Centre Dana-Farber Cancer Institute in Boston, Massachusetts, US.

The full posters presented at EHA can be found on the company webpage at https://www.oncopeptides.com / Investors & media / Presentations / 2019 EHA.

According to the company, the results from the O-12-M1 study demonstrate that melflufen can offer disease stabilisation and favourable time to the next treatment. It is strategically important from a health economic perspective and supports the potential that melflufen may play an important role in the treatment of patients with RRMM.

ANCHOR is a phase 1/2 trial where melflufen and dexamethasone is dosed in combination with either bortezomib or daratumumab. All patients must have 1-4 prior lines of therapy and be refractory (or intolerant) to an immunomodulary agent (IMiD) or a proteasome inhibitor (PI) or both. This trial is currently open for enrolment at multiple sites globally.

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat haematological cancers.